Market Cap
US$350.7m
Last Updated
2019/12/06 00:12 UTC
Data Sources
Company Financials +
Executive Summary
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with high growth potential.
Share Price & News
How has Zynex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZYXI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-7.1%
ZYXI
-0.6%
US Medical Equipment
-1.2%
US Market
1 Year Return
222.6%
ZYXI
21.1%
US Medical Equipment
15.5%
US Market
Return vs Industry: ZYXI exceeded the US Medical Equipment industry which returned 21.1% over the past year.
Return vs Market: ZYXI exceeded the US Market which returned 15.5% over the past year.
Shareholder returns
| ZYXI | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.1% | -0.6% | -1.2% |
| 30 Day | 12.5% | 5.3% | 1.4% |
| 90 Day | 6.0% | 3.0% | 4.7% |
| 1 Year | 231.3%222.6% | 22.2%21.1% | 18.0%15.5% |
| 3 Year | 3060.4%2976.9% | 93.2%87.5% | 44.8%35.4% |
| 5 Year | 8045.4%7830.2% | 121.8%97.7% | 67.3%48.9% |
Price Volatility Vs. Market
How volatile is Zynex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does The Zynex, Inc. (NASDAQ:ZYXI) Share Price Fall With The Market?3 weeks ago | Simply Wall St
Are Zynex, Inc.’s (NASDAQ:ZYXI) High Returns Really That Great?1 month ago | Simply Wall St
What Kind Of Shareholder Appears On The Zynex, Inc.'s (NASDAQ:ZYXI) Shareholder Register?Valuation
Is Zynex undervalued compared to its fair value and its price relative to the market?
46.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZYXI ($10) is trading below our estimate of fair value ($18.55)
Significantly Below Fair Value: ZYXI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZYXI is good value based on its PE Ratio (35.3x) compared to the Medical Equipment industry average (46.4x).
PE vs Market: ZYXI is poor value based on its PE Ratio (35.3x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: ZYXI is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: ZYXI is overvalued based on its PB Ratio (19.7x) compared to the US Medical Equipment industry average (4.2x).
Next Steps
Future Growth
How is Zynex forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
28.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZYXI's forecast earnings growth (28.9% per year) is above the savings rate (1.7%).
Earnings vs Market: ZYXI's earnings (28.9% per year) are forecast to grow faster than the US market (14.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ZYXI's revenue (28.7% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: ZYXI's revenue (28.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ZYXI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Zynex performed over the past 5 years?
71.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZYXI has high quality earnings.
Growing Profit Margin: ZYXI's current net profit margins (22.6%) are lower than last year (33.3%).
Past Earnings Growth Analysis
Earnings Trend: ZYXI has become profitable over the past 5 years, growing earnings by 71.6% per year.
Accelerating Growth: ZYXI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ZYXI had negative earnings growth (-10.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (28.3%).
Return on Equity
High ROE: ZYXI's Return on Equity (55.9%) is considered outstanding.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Zynex's financial position?
Financial Position Analysis
Short Term Liabilities: ZYXI's short term assets ($18.6M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: ZYXI's short term assets ($18.6M) exceed its long term liabilities ($3.8M).
Debt to Equity History and Analysis
Debt Level: ZYXI is debt free.
Reducing Debt: ZYXI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: ZYXI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ZYXI has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: ZYXI has a high level of physical assets or inventory.
Debt Coverage by Assets: ZYXI's debt is not covered by short term assets (assets are -2.0984522463733E+16x debt).
Next Steps
Dividend
What is Zynex's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ZYXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ZYXI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZYXI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZYXI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZYXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Zynex's salary, the management and board of directors tenure and is there insider trading?
1.7yrs
Average management tenure
CEO
Thomas Sandgaard (60yo)
23.9yrs
Tenure
US$1,085,475
Compensation
Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD1.09M) is below average for companies of similar size in the US market ($USD1.71M).
Compensation vs Earnings: Thomas's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Management Age and Tenure
1.7yrs
Average Tenure
Experienced Management: ZYXI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Age and Tenure
1.9yrs
Average Tenure
60.5yo
Average Age
Experienced Board: ZYXI's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 100,000 |
| Max Price | US$10.38 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 3,750 |
| Max Price | US$8.25 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 218,000 |
| Max Price | US$8.57 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 25,000 |
| Max Price | US$7.24 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 48,008 |
| Max Price | US$4.41 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Thomas Sandgaard (60yo)
Founder
- Tenure: 23.9yrs
- Compensation: US$1.09m
Chris Brown
Vice President of Sales & Marketing
- Tenure: 0.8yrs
Dan Moorhead (47yo)
Chief Financial Officer
- Tenure: 2.5yrs
- Compensation: US$404.18k
Joachim Sandgaard
Information Systems Manager
- Tenure: 0yrs
- Compensation: US$92.00k
Giuseppe Papandrea
Chief Operating Officer
- Tenure: 0.4yrs
Board Members
Barry Michaels (69yo)
Director
- Tenure: 1.9yrs
- Compensation: US$116.25k
Thomas Sandgaard (60yo)
Founder
- Tenure: 23.9yrs
- Compensation: US$1.09m
Michael Cress (61yo)
Director
- Tenure: 1.9yrs
- Compensation: US$106.52k
Josh Disbrow (44yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$113.08k
Company Information
Zynex, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zynex, Inc.
- Ticker: ZYXI
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$350.680m
- Shares outstanding: 32.74m
- Website: https://www.zynex.com
Number of Employees
Location
- Zynex, Inc.
- 9555 Maroon Circle
- Englewood
- Colorado
- 80112
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZYXI | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Feb 2004 |
Biography
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stim ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/06 00:12 |
| End of Day Share Price | 2019/12/05 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.